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Abstract
Cerebral palsy (CP) is a heterogenous condition, with level of disability ranging from
immaterial to profound. In concert with the continuum of level of severity of disability/
independent functioning, health care needs, therapies, medications, surgical interven-
tions, costs of care, daily demands on parents and other family members, and expectations
for the future in terms of education, employment, and other milestones of life all vary
widely. Similarly, life expectancy in CP follows a continuum, from far lower than to
potentially as high as general population life expectancy, that parallels the continuum of
levels of disability. Here we review the literature documenting this, and examine the
specific factors that are known to be strongly associated with mortality and longevity in
CP. We also examine the evidence regarding causes of death in CP, and present some new
findings related to this. Finally, we outline important methodological considerations for
future research in this area.
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1. Introduction
Just as Americans headed home for the year-end holidays, the Centres for Disease Control and
Prevention (CDC) issued its annual report on mortality—which had no news to celebrate.
According to the report, published on December 21st, life expectancy in America fell in 2016,
for the second year in a row. An American baby born in 2016 can expect to live on average
78.6 years, down from 78.9 in 2014. The last time life expectancy was lower than in the
preceding year was in 1993. The last time it fell for two consecutive years was in 1962-1963. -
The Economist, 4 January 2018 [1].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The concept of life expectancy is familiar to most people by virtue of reports in newspapers,
online sources, or on television or radio. Comparisons of life expectancy at birth in various
industrialized countries are common, and thus many people may know or will not be sur-
prised to find that life expectancy is higher in Japan than it is in the US, or that in Russia it is
lower than in most countries of Europe. Many may also have some general ideas as to why
such differences may exist: diet, exercise, smoking prevalence, access to healthcare may all
contribute. Mortality is the ultimate endpoint for studies of health and wellbeing, and life
expectancy is one way to summarize the survival and mortality experiences of different groups
of people.
Few give much thought as to how exactly we can know that life expectancy in America fell in
2016, as The Economist reports [1]. To fully understand how we can know that (or know that
life expectancy in Japan is higher than it is in the US, or that life expectancy for the Hispanic
population in the US is greater than it is for people in the US overall, or that women have a
greater life expectancy than men almost universally), one needs to understand what life
expectancy is, and how it is calculated. In this chapter we will begin with a brief review of the
life table, the principle tool used by demographers, actuaries, biostatisticians and epidemiolo-
gists in examining questions of life expectancy. In these contexts, life expectancy has a very
specific meaning, and must not be confused with the actual survival time of a given individual.
Just as it is known that life expectancy in Japan is greater than in the US, it is also known that
life expectancy for groups of people with differing medical conditions, behavior patterns, or
professions can differ. It is probably not surprising, for example, that children born with
complex congenital heart defects have a lower life expectancy than that of any general popu-
lation (GP) of age- and sex-matched children (including all comers, with or without heart
defects). Similarly, persons with various types of cancer have life expectancies that are lower
than those of age- and gender-matched populations (including all comers with or without
cancer). Within the population of children born with congenital heart defects, or persons with
cancer, variation in life expectancy exist as the group is sub-divided according to level of
complexity of heart defects, or site/stage/grade/histology of tumor. Similar statements apply
when considering the life expectancy in cerebral palsy (CP). That people with cerebral palsy
compose a heterogeneous group will be well understood by most readers of this chapter; as we
shall see, the life expectancy of the group as a whole and of meaningfully defined subgroups
differ dramatically as a consequence.
The life expectancy of persons with cerebral palsy (CP) is of interest to many audiences for
varying reasons. Parents would like to know how long they might have to fulfill the often-
challenging physical, emotional, and monetary demands of caring for a child with special
needs; they wonder how long they might get to enjoy the rewards of that relationship and
wonder and worry whether their child might outlive them. Resource allocation for long-term
care facilities depends in part on their residents’ longevity, a fact of interest to governments or
private insurance companies providing funding for such facilities. Life insurance and struc-
tured settlement underwriters must consider life expectancy and other information in a life
table in pricing insurance or annuities. Finally, and perhaps most controversially, in cases of
litigation related to medical care and treatment alleged to have contributed to an outcome of
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CP, life expectancy can be a critical factor in developing and valuing a life-care plan, the
expected present value of which may be a large part of potential damages in such litigation.1
Our interest in this chapter is to provide information based on sound scientific principles and
evidence.
2. The life table and survival curve
Life expectancy (LE) is the arithmetic average survival time remaining for a cohort, hypothet-
ical or real. In more technical statistical terms, it is the expected value of a population of
random survival times. Alternatively, one can think of it as the average survival time for an
individual member of a given population or cohort if such an individual could (hypothetically)
live life over and over again.
In order to understand the meaning of life expectancy, and to gain insight into the questions
posed above, a basic understanding of the life table is extremely helpful. As we shall see,
information presented in a life table can also be set out in, or gleaned from, a survival curve.
An understanding of the relationship between the life table and its corresponding survival
curve will be helpful in understanding life expectancy per se, and in understanding the con-
nection between many studies of long-term survival of children and adults with cerebral palsy,
many of which report survival curves or the equivalent, and life tables and life expectancy.
2.1. The life table
Table 1 is an abbreviated version of the latest life table (2017 table based on 2013 data) for all
US persons (males and females combined) from the US National Center for Health Statistics
(NCHS) [2]. Life expectancy at each whole integer age is given in the column labeled e(x). We
can see from Table 1, for example, that the LE in the US is 78.8 years at birth; 50.1 remaining
years at age 30 years; 23.2 remaining years at age 60; and 2.3 remaining years at age 100.
Generally, the meaning of LE is the average remaining lifespan from a given age. This is not to
be confused with the age to which a cohort of a given age is expected to live. Thus LE is 78.8
remaining years, to age 78.8, for newborns of age 0; it is 2.3 remaining years, to age 102.3, for
those fortunate enough to survived to age 100.
In addition to LE, a life table provides other information, including (for example) (1) the
likelihood that a person born today will be alive at age 50, 80, or 100; (2) the 5-year survival
probability from any age; (3) the probability of surviving beyond age 70; (4) the median
survival time, that is, the time at which half of the hypothetical cohort will have died and
beyond which half will continue to live; and (5) the conditional probability of living to age 65
given one has already lived to age 40. Depending on the context, any of these figures may be of
greater interest or importance than the LE at a given age; however, LE is the most often cited
1
For full disclosure, we acknowledge that we, the authors of this chapter, have provided expert opinions on behalf of both
plaintiffs and defendants in such legal cases, and will undoubtedly do so in the future.
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summary measure of survival. For further details about the columns of the life table and their
inter-relationships, the reader is directed to the many references included below [2–6].
2.2. Survival curves
We now focus on age and the column l(x) of Table 1. If we divide the figures in the l(x) column
by the radix of the table (l(0) = 100,000), we obtain the probability of survival to each age. Figure 1
plots the resulting survival probabilities against age, the survival curve corresponding to the full
US life table (males and females combined).
The unabbreviated version of the life table [2] and the corresponding survival curve (Figure 1)
provide essentially the same information. The area under the survival curve equals the LE
calculated in the life table; if a line vertical line is drawn at any given age in the survival curve
figure, the area under the curve (and bounded by the x- and y-axes) from that point to the right
will be the life expectancy at that age. In Figure 1, the area under the curve from age 70 to age
Age l(x) d(x) q(x) m(x) L(x) T(x) e(x)
0 100,000 596 0.006 0.0060 99,702 7,882,920 78.8
1 99,404 42 0.000 0.0004 99,383 7,783,218 78.3
2 99,362 25 0.000 0.0003 99,350 7,683,835 77.3
3 99,337 18 0.000 0.0002 99,328 7,584,486 76.4
4 99,318 16 0.000 0.0002 99,311 7,485,158 75.4
5 99,303 14 0.000 0.0001 99,295 7,385,847 74.4
6 99,288 13 0.000 0.0001 99,282 7,286,552 73.4
7 99,275 12 0.000 0.0001 99,270 7,187,270 72.4
8 99,264 10 0.000 0.0001 99,259 7,088,000 71.4
9 99,254 9 0.000 0.0001 99,249 6,988,742 70.4
10 99,244 9 0.000 0.0001 99,240 6,889,493 69.4
20 98,953 70 0.001 0.0007 98,918 5,898,013 59.6
30 98,062 105 0.001 0.0011 98,009 4,912,689 50.1
40 96,811 165 0.002 0.0017 96,729 3,937,892 40.7
50 94,352 390 0.004 0.0041 94,157 2,980,312 31.6
60 88,788 785 0.009 0.0089 88,395 2,061,381 23.2
70 78,308 1475 0.019 0.0190 77,570 1,220,609 15.6
80 57,879 2854 0.049 0.0506 56,453 528,563 9.1
90 24,208 3443 0.142 0.1534 22,486 110,867 4.6
100 1971 703 0.357 0.4411 1620 4540 2.3
Table 1. Life table of the US general population, 2017 [2].
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110 (the end of the figure) has been shaded. If one counts the shaded rectangles (and fractions
thereof) and divides by the probability of survival to age 70 (0.78308), one will find a number
close to the e(x) number for age 70 in the life table, namely 15.6 remaining years (which would
be to age 85.6).
This connection between the life table and the area under the survival curve gives a way to
visualize the implications for life expectancy of evidence provided in many studies of CP survival.
Figure 2 provides a hypothetical, but typical, survival curve for children with relatively severe CP
Figure 1. Survival curve for the US GP, 2013. Total area under the survival curve is equal to the life expectancy at birth.
Area under the curve from age 70 (shaded in yellow) is estimated by T(70) ÷ 100,000 in the life table, 1,220,609 person-
years ÷ 100,000 persons = 12.2 years. This can be estimated in the figure by counting rectangles in the shaded area. This
area, normalized by dividing by the probability of survival to age 70, 0.78308, is equal to the life expectancy at age 70:
12.2 years ÷ 0.78308 = 15.6 remaining years.
Figure 2. Survival curve for US GP (green) and a cohort with relatively severe CP (orange), from age 5 to age 35. The area
under the CP survival curve must clearly be less than that under the GP curve, even if we extend the curves to ages above
100. Methods for extrapolating the CP curve to old ages have been discussed and tested in the literature [3, 5–7].
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from age 5 to 35 years. On the same figure, we include the corresponding GP survival curve over
the same ages. One can immediately see that the area under the CP curve has to be less than that
below the GP curve, and this would be true even if both curves extended to ages over 100 years.
Published studies of survival of CP (or almost any medical condition) provide estimates of
survival across a limited age span - but survival to all ages is needed to estimate life expectancy.
Thus some method of extrapolating information to ages 100 or beyond is necessary to use such
empirical evidence to estimate life expectancy.
An in-depth explanation of the issues involved in such extrapolations is beyond the scope of
this chapter. Descriptions and comparisons of various methods may be found in the references
cited below [3, 5–7]. In the next section, we review the factors that have been shown to be
strongly associated with long-term survival in CP.
3. Factors associated with long-term survival, mortality risk, and thus with
life expectancy in CP
In the preceding section, we provided a general introduction to the concept of life expectancy
and touched upon the idea that persons with various medical conditions may have life expec-
tancies lower than those of age- and gender-matched general populations. In this section we
identify the main factors associated with longevity and life expectancy in CP. We will delineate
these factors roughly in order of importance, beginning with those having the greatest poten-
tial impact on life expectancy. The reader should keep in mind, however, that everything is
relative in this regard. Thus, while gross motor functioning may rightly be identified as a
major factor, and often the most significant factor effecting life expectancy in CP, for those
with only minor deficits in gross motor functioning, another factor may in fact be more
relevant. Thus, for any given individual or group, the factors identified in this section may
need to be re-ordered for importance.
3.1. Gross motor functioning
“The contraction of the muscle…causes dilation of the arterioles, capillaries, and lymph
spaces, allowing more oxygenized blood to flow to the muscular fibers, which abstract from it
what they require for their nutrition and let the remainder, together with used-up material,
pass partly into the veins, partly into the lymph spaces and the lymphatic vessels. By this
process the muscle is nourished, the products of decomposition are removed, metabolism is
promoted, and heat is produced.…
The most natural of all muscular exercises, as pointed out by Hippocrates, is walking exercise.
A great part of all the muscles in the body is activated by it; the action of the heart and
respiratory organs is increased; the blood is passed with greater force from the heart into the
blood vessels of the body, which are obliged to contract more vigorously, carry more blood to
the different organs of the body, nourish the latter, and are themselves nourished through their
work.” Sir Herman Weber, On the Influence of muscular exercise on longevity. 1918 [13].
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It has long been understood that voluntary physical activity helps promote health and longev-
ity, and that, conversely, a sedentary lifestyle leads to elevated risk of morbidity and mortality
[8–13]. The negative consequences of involuntary inactivity, after injury, illness, or surgery,
have also been documented [14]. That the limitations in volitional gross motor functioning that
often manifest in persons with CP might negatively impact survival and life expectancy should
therefore come as no surprise. Nevertheless, clear evidence of this association for CP and other
encephalopathies affecting gross and fine motor functioning was not published before 1990.
In 1990, a Special Article published in the New England Journal of Medicine reported on the life
expectancy of severely neurologically disabled people [15]. Drawing on the recent work that
had identified severe intellectual disability (or mental retardation, as it was called at the time)
as a marker for mortality rates far exceeding those of age- and gender-matched GPs [16], the
study provided life tables stratified by level of disability. For the first time in a major medical
journal, level of gross motor functioning emerged as a profound indicator of elevated mortality
risk: Life expectancy for immobile children were reported to be less than 10% of age-matched
GP life expectancy, and less than 20% that of ambulatory children with comparable levels of
intellectual disability. Unfortunately, the article had a serious flaw that rendered all actual life
expectancy figures too low, and all mortality rates too high by something on the order of a
factor of 3.
Subsequent evaluations of life expectancy of CP specifically based on the same source of data
(but without errors of arithmetic) have subsequently been reported and have confirmed what
was perhaps the primary finding in the NEJM Special Article: life expectancy varies on a
seeming continuum with level of independent gross motor functioning. Evidence in support
of this hypothesis is abundant now, coming from numerous countries around the globe.
Examples are easily found in the references at the end of this chapter. A summary of life
expectancy estimates per se will be found in a recent review of literature from 1990 to 2014
[7]. Life expectancy for young children range from as low as 15 remaining years for those with
little or no purposeful gross motor functional ability, to nearly as high as that of their peers in
the GP for those who are able to walk without difficulty (and who have no other significant
comorbidities related to their CP).
3.2. Fine motor functioning and feeding ability
In published studies, the ability to dress independently and to feed oneself have served as
surrogates for overall fine motor functioning, and the connection to longevity is again straight-
forward: The greater the independent abilities in these areas, the longer the life expectancy.
Numerous studies from California have focused on feeding ability [17–21]. Studies from
England have focused on combinations of self-feeding and dressing abilities [22–27], and one
study from Israel accounted for independent/non-independent feeding ability [28]. The associ-
ation of mortality risk with fine motor functioning is not nearly as strong as with gross motor
functioning, and a number of studies have not addressed this factor at all. Thus, if one is able to
account for a specific category of gross motor functioning, a further adjustment for precise
levels of fine motor functioning would be expected to have a smaller impact, all else being
equal.
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As we have alluded to above, the issue of enteral nutrition (via gastrostomy or otherwise)
deserves special attention, and a number of studies have addressed this to one degree or
another [17–20, 28–32]. Taken as a whole, these studies provide evidence of a strong associa-
tion between placement of (and need for) a feeding tube with elevated mortality risk, all else
being equal. Of course, association is not causation, and a number of reviews have pointed out
the difficulties in interpretation of this association [33–37]. As one noted, “Mortality rates
range from 7 to 29% but there is no way to ascertain the degree to which mortality can be
attributed to the intervention” [33].
3.3. Intellectual disability
Historically, level of intellectual disability has been considered a strong driver of mortality
rates and survival of people with a wide variety of neurological disabilities. Within the cate-
gory of CP, level of intellectual disability may be of great importance for those whose gross
and fine motor functional abilities are high; for those who are immobile and unable to feed
themselves, the further impact of level of intellectual disability is small.
3.4. Epilepsy/seizures
Many studies have addressed the association of epilepsy, including remote symptomatic
epilepsy, with elevated risk of mortality as a general medical condition, irrespective of any
underlying disability [38, 39]. For remote symptomatic epilepsy, comparisons of mortality with
the GP may be misleading, as some of the excess may be associated with an underlying brain
injury or other neurological condition precipitating the seizures. A California study attempted
to measure excess mortality risk associated with seizures by focusing on people with mild
developmental disabilities and comparing mortality among those with and without a history
of seizures [40, 41]. In studies of CP seizures have also been shown to be markers for excess
mortality, above and beyond the excess mortality risk associated with limitations in mobility or
feeding ability and other CP-associated disabilities [17, 18, 42, 43]. The relative impact of
epilepsy on life expectancy is greater for those with greater levels of independent gross motor
functioning.
The reason for the elevated risk of mortality in CP associated with seizures is likely multifac-
torial. First, as we will see in a subsequent section, seizures and convulsions do manifest as a
cause of death in CP, and thus a direct link with mortality is evident. The presence of seizures
may also be a marker for overall more involved brain injuries, which in turn may be associated
with greater risk of long-term morbidity and mortality. And finally, some anti-epileptic drugs
are associated side-effects that can be life threatening, including toxicities, liver failure, anemia,
metabolic acidosis, and thrombocytopenia, among others [44, 45].
3.5. Visual and auditory disability
There is little evidence to suggest that auditory or visual disabilities impact directly on mortal-
ity risk in cerebral palsy. One Australian study did include deafness and blindness among five
“additional impairments” that they found to have a significant impact on mortality rates after
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accounting for level of gross motor impairment [43]. A number of studies from the UK
identified severe visual disability as marker for elevated mortality [23, 25–27]. It may be that
these disabilities are more common among more severely disabled people, and thus they may
serve as a marker for overall level of brain injury.
3.6. Other issues
There are any number of additional factors relative to survival and mortality of persons with
CP that have, to date, not been studied extensively. Factors that may well have some further
impact on life expectancy, beyond the major known factors discussed above, are listed in
Table 2.
4. Causes of death in CP
Life expectancy in CP is lower than expected in age- and gender-matched GPs. The question
naturally arises as to what causes of death are driving the higher mortality rates and lower life
expectancies, in this population? A number of studies have addressed this question, most
focusing on either underlying cause of death or immediate (principal, primary) cause of death
[24, 27, 42, 46–51]. At least two studies were vague as to whether an immediate cause or
underlying cause was identified [52, 53]. Most of these studies relied on information reported
in death certificates, [24, 27, 42, 46–51, 54] with at least one basing cause of death on a review of
medical records from the time of death [53]. An underlying cause of death is meant to be the
medical condition or other event that started a chain of events ending in death due to an
immediate cause. In this section we will highlight some of the main underlying and immediate
causes of death that have been found to be more common in CP than in the GP, and a few that
are in fact less common.
Factor Comment
Hydrocephalus Level of risk diminishes with age but risk of infection and malfunction of ventriculoperitoneal shunt
may persist across the lifespan.
Scoliosis,
kyphosis
Severe cases may impact heart and lung function; surgical intervention is relatively safe and effective in
such cases.
Frequent
aspiration
Related to swallowing dysfunction, dysphagia, paletopharyngeal incoordination, or gastroestophageal
reflux; leading to aspiration pneumonia or other respiratory infections.
Contractures May impact negatively on survival given that they can further limit volitional movement.
Decubitus ulcers Pose infection risk. More common among less mobile, and are part of the reason for excess mortality
risk associated with immobility.
Tracheostomy Poses infection risk. At least one study of people with developmental disabilities reported an excess
mortality risk of about 1% across all ages.
Ventilator Poses risk independent of tracheostomy.
Table 2. Other issues that may be associated with excess mortality risk beyond the major factors discussed in preceding
sections.
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Figures 3 and 4 shows the distribution of the leading immediate and underlying causes of
death among 26,677 deaths in the US from 2005 to 2014 that mentioned CP anywhere on the
death certificate (immediate cause of death, underlying cause, contributing cause, or other
significant condition).2 Figure 3 shows the top 4 broad categories of immediate cause of death
(accounting for 73% of all 26,677 deaths) as originally reported on death certificates [55], and as
coded in the National Center for Health Statistics (NCHS) Multiple Cause of Death Records
[56]. Figure 4 similarly reports the distribution of the leading underlying causes of death (top 5
broad categories, accounting for 74% of all 26,677 deaths), but recoding some underlying
causes originally attributed to CP on death certificates and in the NCHS death records (see
next section for details on the recoding). Figures 3 and 4 both report primarily broad categories
Figure 3. Top four broad categories and corresponding subcategories of immediate cause of death among deaths with a
mention of CP on the death certificate.
2
Such analyses of death certificate information do not capture all deaths of people with CP, of course, as in some cases
(cases of very mild CP, or when a death clearly had no connection to CP) CP is not mentioned on the death certificate.
Other studies have estimated that approximately 40-50% of deaths of people with CP include no mention of CP on the
death certificate [24, 43, 47].
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of causes of death as classified by the World Health Organization’s International Statistical
Classification of Diseases and Related Health Problems, tenth revision (ICD 10) [57], though in
some of the studies to be referenced, an earlier revision of the ICD was employed.
4.1. Cerebral palsy as immediate or underlying cause of death in CP
As Figure 3 (immediate causes of death) illustrates, CP (ICD 10 G80) was identified in US
national death records as being the immediate cause of death in a substantial number of cases
(19.5% of the leading causes, or 14.5% of all deaths). CP was far more common as an underly-
ing cause of death among deaths including CP as any cause or contributing factor: initially,
59% of underlying causes of death were attributed to CP. We recoded these, when possible, to
be (a) the last cause listed in Part 1 of a death certificate if that cause was not CP; or (b) the
penultimate cause in Part 1 if one existed. After recoding, CP accounted for 10% of all under-
lying causes, or 13.8% of the top 5 leading causes (Figure 4). Many studies of causes of death in
CP that have relied on death certificate information have reported CP itself to be among the
most common underlying causes [24, 27, 46, 47, 49, 50]. Some authors have considered CP to
Figure 4. Top five broad categories and corresponding subcategories of underlying cause of death among deaths with a
mention of CP on the death certificate.
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be “uninformative”, or “not valid”, as an underlying or principal cause of death [46, 58], and
various methods of recoding such deaths have been undertaken [47, 51, 58]. That CP is often
recorded as the underlying cause of death on death certificates may be unfortunate, as it is
indeed somewhat uninformative.
4.2. Respiratory diseases (ICD 10 J00–J99)
Respiratory diseases have consistently been reported to be among the leading causes of death
among children and adults with CP [24, 27, 43, 46–53]. Figures 3 and 4 shows that, among
deaths with any mention of CP on a death certificate, respiratory diseases were the most
common immediate cause of death (39.7% of the top 4 causes of death, 29.5% of all deaths)
and also the most common underlying cause after recoding many deaths originally attributed
to CP (32.4% of the top 5 causes, 23.7% of all deaths).
Those with more severe levels of disability are at greater risk of mortality due to respiratory
diseases. Standardized mortality ratios (SMRs) have been reported from as low as 10 or below
in older ages for those with less severe disability, to as high as 600 or more at younger ages for
those with more severe levels of disability [46]. Among respiratory diseases, pneumonias, and
in particular pneumonia related to aspiration of solids or liquids, are common [24, 42, 43, 46–
49, 52, 53] and the excess in observed deaths due to this cause is again more pronounced in
those with greater levels of disability [46].
4.3. Circulatory diseases (I00–I99)
Circulatory diseases are also elevated in frequency as a cause of death in CP, and is a common
cause of death in this population, though this is primarily evidenced in deaths that occur at
older ages (as is the case in the GP as well) [27, 46, 47, 51]. Figures 3 and 4 show circulatory
diseases to be the second leading immediate cause of death, and the fourth leading underlying
cause (the latter after recoding of underlying causes of death with underlying cause originally
attributed to CP).
4.4. Diseases of the nervous system (G00–G99)
The broad category of diseases of the nervous system includes CP itself (G80), as we have
discussed above. Even after recoding deaths that are attributed to CP, it remains as a signifi-
cantly common underlying cause of death (Figure 4), but other nervous system diseases
become more prominent. Among the most common underlying causes of death within this
broad category other than CP itself are seizures and hydrocephalus [51, 52].
4.5. Sepsis
Sepsis is an often life threatening condition caused by the body’s system-wide inflammatory
response to infection. Sepsis is a common cause of death in CP and in the GP, particularly in
the elderly, the very young, or in those with severe disabilities or compromised immune
systems. Because the ICD 10 classifies disease according to body system or, in the case of
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infection, according to specific organism, sepsis is spread throughout its hierarchy, and across
many of the broad categories of causes of death illustrated in Figures 3 and 4. Among the
26,677 deaths in the US from 2005 to 2014 that included CP anywhere on the death certificate,
sepsis was noted to be the immediate cause in 1628 deaths (6.1%). Among these deaths, 98%
were coded as ICD 10 A41 (other sepsis), of which most (97%) were coded as A41.9 (sepsis,
unspecified organism).
4.6. Neoplasms, cancer (C00–D46)
Cancers, including both malignant and benign tumors, were an underlying cause of death in
only 924 records out of the 26,677 deaths contributing to the analyses of Figures 3 and 4, thus
not a leading immediate or underlying cause of death, and not included in those figures.
Nevertheless, some interesting results have been reported regarding cancer mortality in CP.
A large California study reported that those with CP were at greater risk of death due to cancer
of the esophagus (SMR = 5.4, 95% CI 3.1–8.8), colon (2.2, 1.4–3.3), liver (2.2, 1.1–4.1), breast (1.8,
1.2–2.6), and bladder (4.6, 2.1–8.7); but at a five-fold decreased risk of death due to cancer of
the trachea, bronchus and lung (SMR = 0.2, 0.1–0.4) [59]. The number of cancer deaths is likely
small due primarily to its typical manifestation in older ages, ages to which many with more
severe levels of CP do not live owing to competing risks.
4.7. Other “uninformative” causes of death
Another category of causes that appears frequently on deaths certificates of persons with CP is
“symptoms, signs, and abnormal results of clinical and laboratory tests, not classified else-
where,” (ICD 10 R00–R99). These causes have been considered to be uninformative (or per-
haps uninteresting) [46]. Referring again to Figure 4, we see that this category was the second
leading underlying cause in US deaths from 2005 to 2014 (after recoding as described above),
accounting for 22.2% of the top five leading cause categories, or 16.3% of all 26,677 deaths.
However, given that this category includes “convulsions, not elsewhere classified,” (ICD 10
R56) which in some cases account for up to half of deaths in this category, and also includes
deaths related to unspecified respiratory and circulatory system problems, which in one study
accounted for more than half of all deaths in this category (ICD 10 R56) [51, 58], more careful
scrutiny of this broad category may be warranted. When comparing results from various
studies as to the most common underlying or immediate cause of death in CP, it should be
borne in mind that some studies omit this, and other, categories from consideration.
5. Methodological considerations for future research
The studies cited and discussed in the foregoing sections of this chapter provide a wealth of
information about long-term survival, mortality, and life expectancy of people with cerebral
palsy. Many questions remain to be answered, however, and more studies will undoubtedly be
carried out in the future in an attempt to answer them. The questions such researchers will face
in planning and executing their studies will be many and complex, and a full discussion of all
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factors that ought to be considered is beyond the scope of this chapter. In this section, we
mention a few of the most important methodological considerations for future studies in the
broad context of questions about CP survival and life expectancy. We will also point to a few
areas of research that remain poorly explored but important.
5.1. External validity
In previous sections of this chapter, we have identified a number of risk factors that are known to
be strongly associated with survival and life expectancy in CP. One of the most important factors
is gross motor functioning, and any study of survival in CP must account for this. However, as
the literature to date has demonstrated, there are many ways to form cohorts based on combi-
nations of this and other functional abilities. Therefore, for the sake of comparing results across
time and place, we advise forming cohorts according to Gross Motor Function Classification
System (GMFCS) [60] level or other commonly employed measures of gross motor functioning.
For similar reasons, when possible, scales such as the Manual Ability Classification System
(MACS) [61], the Communication Function Classification System (CFCS) [62], and the Eating
and Drinking Ability Classification System (EDACS) [63] should be utilized. Other factors to
account for can be gleaned from Section 4, perhaps chief among them gastrostomy status. Some
studies will be limited by data that has been collected historically, but prospective studies should
seize the opportunity to measure and report results in a more standardized fashion.
5.2. Time-based biases
Consider the 2000 UK study by Hutton et al. [24] Figure 1D in this study illustrates survival for
children with severe ambulatory disability (i.e., no independent walking ability) and for
children without severe ambulatory disability. The survival curves begin at age 0. This is
problematic. Was walking ability really measured at age 0? Surely all children would be
considered to have severe ambulatory disability at age 0, by the definition employed in this
study. Furthermore, CP is rarely diagnosed in any child before a year or two of age. These
issues are important: be as precise as possible with regard to when any time varying covariates
are measured, and also as to precisely when (at what age) CP was diagnosed. Failure to do so
can lead to a phenomenon known as immortal time bias, a surprisingly common error in
reports of survival in a variety of populations, [64] including at least one study of survival of
children with neurological disabilities [65].
5.3. Methods for causal inference
Researchers in the fields of Epidemiology, Biostatistics, and Computer Science have collabo-
rated in recent years to develop a framework for robust causal inference [66]. This framework
provides the analytic techniques and needed assumptions for interpreting results obtained
from observational (i.e. non-experimental) studies in a causal way. The framework also pro-
vides tools for thinking more clearly about hypotheses and identifying potential sources of
bias and confounding in conventional analyses. Applying these methods to studies of mortal-
ity in CP may help to unravel complex questions which have thus far been impossible to
address [67]. For example, on the subject of gastrostomy feeding, we might wonder several
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things: (a) how much of the increase in mortality for people with a gastrostomy tube is caused
by the need for a tube versus the placement and presence of the tube itself; (b) what if all
children with CP of a given functional profile were given a gastrostomy tube; or (c) what if no
children with CP of a given profile were given gastrostomy tubes? Given the right data and
careful analysis, even in the absence of an ethically impractical randomized clinical trial [35],
the causal inference framework could help answer these and other important questions.
6. Conclusions
In this chapter we have reviewed the general concepts of life expectancy, life tables, and
survival curves. We reviewed the important predictors of mortality and life expectancy in CP,
as well as the major causes of death common in CP.
Mobility is a strong predictor of mortality in CP, and as a consequence, a strong predictor of
cause of death; in young and old with CP, respiratory diseases figure prominently as a cause of
death, and circulatory diseases become more relevant in older ages. Neurologic disorders are
also a major category of cause of death, even after reclassifying underlying causes initially
attributed to CP to more informative causal categories. Seizures and hydrocephalus are impor-
tant causes in this category as well.
Future research in the mortality and life expectancy of CP should focus on analyzing data
using as many of the previously-identified risk factors as possible and should stratify patients
using widely replicable scales of those factors, such as GMFCS. New tools of causal inference
should be employed to help control bias and confounding in observational studies.
Though much has been learned about life expectancy and causes of death in CP, there is
undoubtedly much to be learned. It is our hope that this review and our recommendations
will help guide future research in its quest to answer the many open questions related to long-
term mortality and survival, and life expectancy in cerebral palsy.
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